Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888510 | 0.92 | KMT2A (0.55) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL31387020 | 0.92 | KMT2A (0.55) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL31310019 | 0.92 | KMT2A (0.55) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL7855942 | 0.91 | KMT2A (0.69) | KMT2AEPHX2CASP3 | |
| SCHEMBL25390706 | 0.89 | KMT2A (0.52) | KMT2AEPHX2CASP3 | |
| SCHEMBL30748702 | 0.89 | KMT2A (0.52) | KMT2AEPHX2CASP3 | |
| SCHEMBL25391589 | 0.89 | KMT2A (0.52) | KMT2AEPHX2CASP3 | |
| SCHEMBL16942065 | 0.89 | KMT2A (0.52) | KMT2AEPHX2CASP3 | |
| SCHEMBL3060297 | 0.88 | KMT2A (0.51) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL31733654 | 0.88 | KMT2A (0.51) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3225251-A1 | MODULATION OF ACTIVITY OF PRONEUROTROPHINS | H. Lundbeck A/S (DK) | 2017-10-04 | — | — | EP | disclosed |
| EP-2120997-B1 | MODULATION OF ACTIVITY OF PRONEUROTROPHINS | H LUNDBECK AS (DK) | 2017-03-01 | — | — | EP | disclosed |
| US-20160060346-A1 | Modulation of Activity of Proneurotrophins | H. LUNDBECK A/S (DK) | 2016-03-03 | — | — | US | disclosed |
| US-9234036-B2 | Modulation of activity of proneurotrophins | H. LUNDBECK A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-20150023971-A1 | Modulation of Activity of Proneurotrophins | H LUNDBECK A/S (DK) | 2015-01-22 | — | — | US | disclosed |
| US-8748384-B2 | Modulation of activity of proneurotrophins | H. LUNDBECK A/S (DK) | 2014-06-10 | — | — | US | disclosed |
| US-7794734-B2 | Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100210523-A1 | MODULATION OF ACTIVITY OF PRONEUROTROPHINS | NEURONICON APS (DK) | 2010-08-19 | — | — | US | disclosed |
| EP-2120997-A2 | MODULATION OF ACTIVITY OF PRONEUROTROPHINS | H. Lundbeck A/S (DK) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074329-A2 | MODULATION OF ACTIVITY OF PRONEUROTROPHINS | NEURONICON APS (DK) | 2008-06-26 | — | — | WO | disclosed |
| US-20070134272-A1 | Mannheimia haemolytica chimeric outer membrane protein PIpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2007-06-14 | — | — | US | disclosed |
| US-7144580-B2 | M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060078572-A1 | M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2006-04-13 | — | — | US | disclosed |
| US-20040156865-A1 | M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060346-A1 | Modulation of Activity of Proneurotrophins | SORT1, BDNF, PRSS12 | KMT2A 4659/4885EPHX2 4384/4885CASP3 3227/4885 |
| US-20150023971-A1 | Modulation of Activity of Proneurotrophins | SORT1, OPRL1, BDNF | KMT2A 4709/4885EPHX2 4429/4885CASP3 3547/4885 |
| US-20100210523-A1 | MODULATION OF ACTIVITY OF PRONEUROTROPHINS | SORT1, BDNF, PRSS12 | KMT2A 4659/4885EPHX2 4384/4885CASP3 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.